{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:30:47Z","timestamp":1793712647322,"version":"4.6.1"},"reference-count":97,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01DK011794"],"award-info":[{"award-number":["P01DK011794"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parathyroid hormone (PTH), produced by the parathyroid glands, plays a critical role in the regulation of calcium and phosphate homeostasis, acting primarily on bone and kidney to maintain serum calcium levels within a narrow range. Parathyroid hormone also plays important roles in bone remodeling by directly stimulating osteoblasts and osteocytes, integrating its calcemic response with stimulation of bone formation. Through the RANK\/RANK-ligand system, these cells activate osteoclasts, promoting a balanced process of bone formation and resorption that maintains bone density and strength. Dysregulation of PTH, as seen in disorders such as hyper- and hypoparathyroidism, can lead to significant clinical complications. In recent years, major advancements have been made in the development of PTH analogs, aimed at leveraging PTH\u2019s physiological effects on bone to treat conditions such as osteoporosis and hypoparathyroidism. While PTH promotes both bone formation and bone resorption, the net outcome may be a gain or loss of bone mass, depending largely on the administration pattern of PTH or its analogs. When PTH is given intermittently (eg, as once-daily subcutaneous injection), bone formation is favored. Continuous administration of PTH or chronic elevation of blood PTH levels as seen in primary hyperparathyroidism tend to promote bone resorption. Parathyroid hormone analogs, such as teriparatide (PTH(1-34)) and the PTHrP analog abaloparatide, administered once daily, have significant efficacy in stimulating bone formation, making them valuable options for the treatment of osteoporosis. Given this capacity to improve bone structure, these analogs hold broader therapeutic potential for other skeletal disorders, including fracture healing and oral bone repair, which expands the scope of PTH-based therapies beyond osteoporosis. Long-acting PTH analogs have applications in treating hypoparathyroidism, offering an alternative to conventional treatment with calcium and active vitamin D. This article reviews the molecular mechanisms of approved and emerging PTH-based medicines, their clinical applications, and recent advances in optimizing their therapeutic potential. We also discuss ongoing research aimed at developing next-generation PTH analogs with improved efficacy for skeletal and metabolic disorders.<\/jats:p>","DOI":"10.1093\/jbmr\/zjaf118","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T11:39:03Z","timestamp":1755862743000},"page":"1195-1206","source":"Crossref","is-referenced-by-count":20,"title":["Advances in Parathyroid Hormone-based medicines"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2261-0216","authenticated-orcid":false,"given":"Anne-Laure","family":"Bonnet","sequence":"first","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital and Harvard Medical School , Boston, MA 02114 ,","place":["United States"]},{"name":"AP-HP, Services de M\u00e9decine Bucco-Dentaire: GH Nord - Universit\u00e9 Paris Cit\u00e9, GH Sorbonne Universit\u00e9, GH Henri Mondor , 94200 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0306-6588","authenticated-orcid":false,"given":"Lizaveta","family":"Aboishava","sequence":"additional","affiliation":[{"name":"MGB Salem Hospital , Salem, MA 01970 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0867-9778","authenticated-orcid":false,"given":"Michael","family":"Mannstadt","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital and Harvard Medical School , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"issue":"5 Pt 2","key":"2025103115324994400_ref1","first-page":"F665","article-title":"Receptors for PTH and PTHrP: their biological importance and functional properties","volume":"277","author":"Mannstadt","year":"1999","journal-title":"Am J Phys"},{"issue":"10","key":"2025103115324994400_ref2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3275\/7925","article-title":"Catabolic and anabolic actions of parathyroid hormone on the skeleton","volume":"34","author":"Silva","year":"2011","journal-title":"J Endocrinol Investig"},{"issue":"3","key":"2025103115324994400_ref3","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/jbmr.3011","article-title":"Control of bone anabolism in response to mechanical loading and PTH by distinct mechanisms downstream of the PTH receptor","volume":"32","author":"Delgado-Calle","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2025103115324994400_ref4","doi-asserted-by":"publisher","first-page":"a031237","DOI":"10.1101\/cshperspect.a031237","article-title":"Regulation of bone remodeling by parathyroid hormone","volume":"8","author":"Wein","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"2025103115324994400_ref5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bcp.13455","article-title":"Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology","volume":"84","author":"Tay","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"43","key":"2025103115324994400_ref6","doi-asserted-by":"publisher","first-page":"16525","DOI":"10.1073\/pnas.0808750105","article-title":"Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation","volume":"105","author":"Okazaki","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2025103115324994400_ref7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/nchembio.1611","article-title":"Endosomal generation of cAMP in GPCR signaling","volume":"10","author":"Vilardaga","year":"2014","journal-title":"Nat Chem Biol"},{"issue":"1","key":"2025103115324994400_ref8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-Type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"issue":"5","key":"2025103115324994400_ref9","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.clinthera.2014.04.001","article-title":"Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study. Clinical trial, phase I, research support, N.I.H., extramural, research support, non-U.S. gov't","volume":"36","author":"Clarke","year":"2014","journal-title":"Clin Ther"},{"issue":"6436","key":"2025103115324994400_ref10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1126\/science.aav7942","article-title":"Structure and dynamics of the active human parathyroid hormone receptor-1","volume":"364","author":"Zhao","year":"2019","journal-title":"Science"},{"issue":"1","key":"2025103115324994400_ref11","doi-asserted-by":"publisher","first-page":"6276","DOI":"10.1038\/s41467-022-34009-x","article-title":"Molecular insights into the distinct signaling duration for the peptide-induced PTH1R activation","volume":"13","author":"Zhai","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"2025103115324994400_ref12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1073\/pnas.68.1.63","article-title":"Synthesis of a biologically active N-terminal tetratriacontapeptide of parathyroid hormone","volume":"68","author":"Potts","year":"1971","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6228","key":"2025103115324994400_ref13","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/bmj.280.6228.1340","article-title":"Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial","volume":"280","author":"Reeve","year":"1980","journal-title":"Br Med J"},{"issue":"19","key":"2025103115324994400_ref14","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"2025103115324994400_ref15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"20","key":"2025103115324994400_ref16","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"2025103115324994400_ref17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"issue":"2","key":"2025103115324994400_ref18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/jbmr.4188","article-title":"Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study","volume":"36","author":"Gilsenan","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2025103115324994400_ref19","doi-asserted-by":"publisher","first-page":"e10665","DOI":"10.1002\/jbm4.10665","article-title":"Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates","volume":"6","author":"Krege","year":"2022","journal-title":"JBMR Plus"},{"issue":"2","key":"2025103115324994400_ref20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0021-9258(18)85007-4","article-title":"The extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regulates the level of blood calcium","volume":"63","author":"Collip","year":"1925","journal-title":"J Biol Chem"},{"issue":"8","key":"2025103115324994400_ref21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism","volume":"276","author":"Winer","year":"1996","journal-title":"JAMA"},{"issue":"9","key":"2025103115324994400_ref22","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium","volume":"88","author":"Winer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025103115324994400_ref23","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1210\/jc.2007-2552","article-title":"Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism","volume":"93","author":"Winer","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025103115324994400_ref24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1210\/jc.2011-1908","article-title":"Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","volume":"97","author":"Winer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2025103115324994400_ref25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jpeds.2018.08.010","article-title":"Long-term parathyroid hormone 1-34 replacement therapy in children with hypoparathyroidism","volume":"203","author":"Winer","year":"2018","journal-title":"J Pediatr"},{"issue":"3","key":"2025103115324994400_ref26","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1080\/00016470152846673","article-title":"Increases in callus formation and mechanical strength of healing fractures in old rats treated with parathyroid hormone","volume":"72","author":"Andreassen","year":"2001","journal-title":"Acta Orthop Scand"},{"issue":"4","key":"2025103115324994400_ref27","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2106\/JBJS.D.02115","article-title":"Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34)","volume":"87","author":"Alkhiary","year":"2005","journal-title":"J Bone Joint Surg Am"},{"issue":"17","key":"2025103115324994400_ref28","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2106\/JBJS.J.01379","article-title":"Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women","volume":"93","author":"Peichl","year":"2011","journal-title":"J Bone Joint Surg Am"},{"issue":"2","key":"2025103115324994400_ref29","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00198-017-4286-7","article-title":"Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur","volume":"29","author":"Greenspan","year":"2018","journal-title":"Osteoporos Int"},{"issue":"4","key":"2025103115324994400_ref30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.12671\/jkfs.2012.25.4.295","article-title":"Intermittent parathyroid hormone treatment for stimulation of callus formation in elderly patients","volume":"25","author":"Song","year":"2012","journal-title":"J Korean Fract Soc"},{"issue":"19","key":"2025103115324994400_ref31","doi-asserted-by":"publisher","first-page":"e3626","DOI":"10.1097\/MD.0000000000003626","article-title":"Teriparatide improves fracture healing and early functional recovery in treatment of osteoporotic intertrochanteric fractures","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine"},{"issue":"22","key":"2025103115324994400_ref32","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.2106\/JBJS.15.01217","article-title":"Effects of teriparatide compared with risedronate on recovery after pertrochanteric hip fracture: results of a randomized, active-controlled, double-blind clinical trial at 26 weeks","volume":"98","author":"Aspenberg","year":"2016","journal-title":"J Bone Joint Surg Am"},{"issue":"11","key":"2025103115324994400_ref33","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1007\/s00198-016-3651-2","article-title":"Aggravation of spinal cord compromise following new osteoporotic vertebral compression fracture prevented by teriparatide in patients with surgical contraindications","volume":"27","author":"Zhao","year":"2016","journal-title":"Osteoporos Int"},{"issue":"5","key":"2025103115324994400_ref34","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/jbmr.3067","article-title":"Effect of teriparatide or risedronate in elderly patients with a recent pertrochanteric hip fracture: final results of a 78-week randomized clinical trial","volume":"32","author":"Malouf-Sierra","year":"2017","journal-title":"J Bone Miner Res"},{"key":"2025103115324994400_ref35","doi-asserted-by":"publisher","first-page":"100217","DOI":"10.1016\/j.bonr.2019.100217","article-title":"The efficacy of osteoporotic treatment in patients with new spinal vertebral compression fracture pain, ADL, QOL, bone metabolism and fracture-healing - In comparison with weekly teriparatide with bisphosphonate","volume":"11","author":"Shigenobu","year":"2019","journal-title":"Bone Rep"},{"issue":"1","key":"2025103115324994400_ref36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.11005\/jbm.2017.24.1.65","article-title":"Current role and application of teriparatide in fracture healing of osteoporotic patients: a systematic review","volume":"24","author":"Kim","year":"2017","journal-title":"J Bone Metab"},{"key":"2025103115324994400_ref37","doi-asserted-by":"publisher","first-page":"6040379","DOI":"10.1155\/2016\/6040379","article-title":"The effect of teriparatide on fracture healing of osteoporotic patients: a meta-analysis of randomized controlled trials","volume":"2016","author":"Lou","year":"2016","journal-title":"Biomed Res Int"},{"issue":"12","key":"2025103115324994400_ref38","doi-asserted-by":"publisher","first-page":"e0168691","DOI":"10.1371\/journal.pone.0168691","article-title":"Effectiveness of teriparatide on fracture healing: a systematic review and meta-analysis","volume":"11","author":"Shi","year":"2016","journal-title":"PLoS One"},{"key":"2025103115324994400_ref39","doi-asserted-by":"publisher","first-page":"e800","DOI":"10.6061\/clinics\/2019\/e800","article-title":"The effectiveness and safety of parathyroid hormone in fracture healing: a meta-analysis","volume":"74","author":"Hong","year":"2019","journal-title":"Clinics (Sao Paulo)"},{"issue":"8","key":"2025103115324994400_ref40","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s00198-021-05847-0","article-title":"Effectiveness of parathyroid hormone (PTH) analogues on fracture healing: a meta-analysis","volume":"32","author":"Eastman","year":"2021","journal-title":"Osteoporos Int"},{"issue":"5","key":"2025103115324994400_ref41","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2106\/JBJS.20.02109","article-title":"Novel parathyroid hormone-based bone graft, KUR-113, in treatment of acute open tibial shaft fracture: a Phase-2 randomized controlled trial","volume":"104","author":"Orbeanu","year":"2022","journal-title":"J Bone Joint Surg Am"},{"issue":"25","key":"2025103115324994400_ref42","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1005361","article-title":"Teriparatide and osseous regeneration in the oral cavity","volume":"363","author":"Bashutski","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"2025103115324994400_ref43","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1177\/0022034511407920","article-title":"Short-term teriparatide delivery and osseointegration: a clinical feasibility study","volume":"90","author":"Kuchler","year":"2011","journal-title":"J Dent Res"},{"issue":"26","key":"2025103115324994400_ref44","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1200\/JCO.19.02192","article-title":"Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial","volume":"38","author":"Sim","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025103115324994400_ref45","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.bjoms.2021.10.004","article-title":"Effective ancillary role and long-term course of daily or weekly teriparatide treatment on refractory medication-related osteonecrosis of the jaw: a clinical case series","volume":"60","author":"Yoshiga","year":"2022","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"12","key":"2025103115324994400_ref46","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s00198-021-06078-z","article-title":"Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis","volume":"32","author":"Dos Santos","year":"2021","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025103115324994400_ref47","doi-asserted-by":"publisher","first-page":"15518","DOI":"10.1038\/s41598-023-42607-y","article-title":"Preventive effect of teriparatide on medication-related osteonecrosis of the jaw in rats","volume":"13","author":"Park","year":"2023","journal-title":"Sci Rep"},{"issue":"5","key":"2025103115324994400_ref48","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"issue":"4","key":"2025103115324994400_ref49","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"2025103115324994400_ref50","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2025103115324994400_ref51","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s12020-023-03355-1","article-title":"Continuous subcutaneous rhPTH infusion for managing difficult chronic hypoparathyroidism. A systematic review","volume":"81","author":"Gamarra","year":"2023","journal-title":"Endocrine"},{"issue":"3","key":"2025103115324994400_ref52","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jpeds.2014.04.060","article-title":"Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism","volume":"165","author":"Winer","year":"2014","journal-title":"J Pediatr"},{"key":"2025103115324994400_ref53","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-20-0009","article-title":"Continuous rhPTH (1-34) treatment in chronic hypoparathyroidism","volume":"2020","author":"Fuss","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"11","key":"2025103115324994400_ref54","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1210\/jc.2011-1359","article-title":"Long-term results of continuous subcutaneous recombinant PTH (1-34) infusion in children with refractory hypoparathyroidism","volume":"96","author":"Linglart","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025103115324994400_ref55","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000479867","article-title":"Continuous subcutaneous recombinant parathyroid hormone (1-34) infusion in the Management of Childhood Hypoparathyroidism Associated with Malabsorption","volume":"89","author":"Saraff","year":"2018","journal-title":"Horm Res Paediatr"},{"issue":"5","key":"2025103115324994400_ref56","doi-asserted-by":"publisher","first-page":"bvae053","DOI":"10.1210\/jendso\/bvae053","article-title":"Continuous subcutaneous delivery of rhPTH(1-84) and rhPTH(1-34) by pump in adults with hypoparathyroidism","volume":"8","author":"Charoenngam","year":"2024","journal-title":"J Endocr Soc"},{"key":"2025103115324994400_ref57","article-title":"Takeda to discontinue manufacturing of NATPAR\/NATPARA for patients with hypoparathyroidism at the end of 2024"},{"key":"2025103115324994400_ref58","first-page":"668","volume-title":"Peptides: the wave of the future: proceedings of the second international and the seventeenth american peptide symposium, 2001","author":"Dong","year":"2001"},{"issue":"5","key":"2025103115324994400_ref59","doi-asserted-by":"publisher","first-page":"e1300","DOI":"10.7759\/cureus.1300","article-title":"Profile of abaloparatide and its potential in the treatment of postmenopausal osteoporosis","volume":"9","author":"Tella","year":"2017","journal-title":"Cureus"},{"issue":"1","key":"2025103115324994400_ref60","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1210\/me.2007-0274","article-title":"Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH\/PTHrP receptor","volume":"22","author":"Dean","year":"2008","journal-title":"Mol Endocrinol"},{"issue":"6","key":"2025103115324994400_ref61","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH","volume":"40","author":"Jilka","year":"2007","journal-title":"Bone"},{"issue":"2","key":"2025103115324994400_ref62","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025103115324994400_ref63","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"2025103115324994400_ref64","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"Activextend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025103115324994400_ref65","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/jbmr.4877","article-title":"Efficacy and safety of transdermal abaloparatide in postmenopausal women with osteoporosis: a randomized study","volume":"38","author":"Lewiecki","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025103115324994400_ref66","doi-asserted-by":"publisher","DOI":"10.1111\/clr.14397","article-title":"Abaloparatide enhances bone regeneration in extraction socket dental implant defects: an experimental in vivo study","volume":"36","author":"Latimer","year":"2025","journal-title":"Clin Oral Implants Res"},{"issue":"2","key":"2025103115324994400_ref67","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/JPER.22-0211","article-title":"Abaloparatide outperforms teriparatide in protecting against alveolar bone loss in experimental periodontitis","volume":"94","author":"Li","year":"2023","journal-title":"J Periodontol"},{"issue":"8","key":"2025103115324994400_ref68","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/jbmr.4016","article-title":"A randomized double-blind placebo-controlled first-in-human phase 1 trial of TransCon PTH in healthy adults","volume":"35","author":"Karpf","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025103115324994400_ref69","doi-asserted-by":"publisher","first-page":"e372","DOI":"10.1210\/clinem\/dgab577","article-title":"PaTH forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism","volume":"107","author":"Khan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025103115324994400_ref70","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/jbmr.4726","article-title":"Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial","volume":"38","author":"Khan","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025103115324994400_ref71","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02843-8","article-title":"Palopegteriparatide treatment improves renal function in adults with chronic hypoparathyroidism: 1-year results from the phase 3 PaTHway trial","volume":"41","author":"Rejnmark","year":"2024","journal-title":"Adv Ther"},{"key":"2025103115324994400_ref72","volume-title":"OSTEOLOGIE","author":"Tsourdi"},{"key":"2025103115324994400_ref73","article-title":"Palopegteriparatide improves skeletal dynamics in adults with chronic hypoparathyroidism: 3-year results from the phase 2 PaTH forward trial","author":"Rubin","year":"2024"},{"issue":"4","key":"2025103115324994400_ref74","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1210\/clinem\/dgae693","article-title":"Efficacy and safety of TransCon PTH in adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway trial","volume":"110","author":"Clarke","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025103115324994400_ref75","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.15961","article-title":"NRF2 in kidney physiology and disease","volume":"12","author":"Bondi","year":"2024","journal-title":"Physiol Rep"},{"issue":"2","key":"2025103115324994400_ref76","first-page":"98","article-title":"Renal function during calcitriol therapy in chronic renal failure","volume":"33","author":"Bertoli","year":"1990","journal-title":"Clin Nephrol"},{"issue":"9752","key":"2025103115324994400_ref77","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"},{"issue":"41","key":"2025103115324994400_ref78","doi-asserted-by":"publisher","first-page":"29821","DOI":"10.1074\/jbc.M705495200","article-title":"1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter","volume":"282","author":"Yuan","year":"2007","journal-title":"J Biol Chem"},{"issue":"6","key":"2025103115324994400_ref79","doi-asserted-by":"publisher","first-page":"ziae045","DOI":"10.1093\/jbmrpl\/ziae045","article-title":"Preclinical development of EXT608, an investigational parathyroid hormone derivative with extended half-life for the treatment of hypoparathyroidism","volume":"8","author":"Hall","year":"2024","journal-title":"JBMR Plus"},{"key":"2025103115324994400_ref80","article-title":"Extend biosciences announces positive data from phase 1 trial of EXT608 for the treatment of hypoparathyroidism"},{"issue":"1","key":"2025103115324994400_ref81","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1038\/s41467-025-59665-7","article-title":"Prolonging parathyroid hormone analog action in vitro and in vivo through peptide lipidation","volume":"16","author":"Hoppner","year":"2025","journal-title":"Nat Commun"},{"issue":"4","key":"2025103115324994400_ref82","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae808","article-title":"MBX 2109, a once-weekly parathyroid hormone replacement therapy prodrug: phase 1, first-in-human, randomized trial","volume":"110","author":"Carney","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2025103115324994400_ref83","article-title":"MBX biosciences presents MBX 2109 phase 2 avail hypoparathyroidism trial rationale and design at the ASBMR 2024 Annual Meeting"},{"issue":"6","key":"2025103115324994400_ref84","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/jbmr.4274","article-title":"Safety and efficacy of oral human parathyroid hormone (1-34) in hypoparathyroidism: an open-label study","volume":"36","author":"Ish-Shalom","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025103115324994400_ref85","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/jbmr\/zjae057","article-title":"Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD or osteoporosis: a randomized, placebo-controlled, 6-month, phase 2 study","volume":"39","author":"Tripto-Shkolnik","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025103115324994400_ref86","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/jbmr.2811","article-title":"Pharmacodynamic actions of a long-acting PTH analog (LA-PTH) in thyroparathyroidectomized (TPTX) rats and normal monkeys","volume":"31","author":"Shimizu","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025103115324994400_ref87","doi-asserted-by":"publisher","DOI":"10.1530\/EC-24-0464","article-title":"Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist","volume":"14","author":"Ovize","year":"2025","journal-title":"Endocr Connect"},{"issue":"9","key":"2025103115324994400_ref88","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae121","article-title":"An open-label phase 2 study of eneboparatide, a novel PTH receptor 1 agonist, in hypoparathyroidism","volume":"109","author":"Takacs","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2025103115324994400_ref89","article-title":"Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO phase III trial"},{"issue":"1","key":"2025103115324994400_ref90","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.1038\/ncomms13384","article-title":"Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism","volume":"7","author":"Tamura","year":"2016","journal-title":"Nat Commun"},{"issue":"7967","key":"2025103115324994400_ref91","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41586-023-06169-3","article-title":"Class B1 GPCR activation by an intracellular agonist","volume":"618","author":"Kobayashi","year":"2023","journal-title":"Nature"},{"issue":"Supplement_1","key":"2025103115324994400_ref92","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/jbmr\/zjae183","article-title":"Characterization of a novel oral small molecule PTH1R agonist: sustained control of serum calcium and modulation of bone biomarkers in TPTx rats suggests a promising therapy for hypoparathyroidism. 2024 Annual Meeting of the American Society for Bone and Mineral Research, September 27-30, 2024","volume":"39","author":"Zhang","year":"2024","journal-title":"J Bone Miner Res"},{"key":"2025103115324994400_ref93","article-title":"Septerna announces discontinuation of SEP-786 phase 1 clinical trial and plans to advance next-generation oral small molecule PTH1R agonist"},{"issue":"Supplement_1","key":"2025103115324994400_ref94","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad114.480","article-title":"SAT182 effects of an orally bioavailable nonpeptide parathyroid hormone receptor type 1 (PTH1R) antagonist in rodent models of primary hyperparathyroidism (PHPT)","volume":"7","author":"Antwan","year":"2023","journal-title":"J Endocr Soc"},{"key":"2025103115324994400_ref95","article-title":"Blocking activation of the parathyroid hormone receptor type 1 (PTH1R) with a specific and orally available antagonist is a promising therapy for the treatment of primary hyperparathyroidism (PHPT)"},{"issue":"1","key":"2025103115324994400_ref96","doi-asserted-by":"publisher","first-page":"13176","DOI":"10.1038\/ncomms13176","article-title":"SIKs control osteocyte responses to parathyroid hormone","volume":"7","author":"Wein","year":"2016","journal-title":"Nat Commun"},{"issue":"10","key":"2025103115324994400_ref97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/endocr\/bqaa141","article-title":"Differentiation of PTH-expressing cells from human pluripotent stem cells","volume":"161","author":"Lawton","year":"2020","journal-title":"Endocrinology"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjaf118\/64113577\/zjaf118.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/11\/1195\/64113577\/zjaf118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/11\/1195\/64113577\/zjaf118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T19:32:58Z","timestamp":1761939178000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/40\/11\/1195\/8240154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":97,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,8,23]]},"published-print":{"date-parts":[[2025,10,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjaf118","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,8,23]]}}}